Ernexa Therapeutics (ERNA) regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock Market. On July 1, 2025, the company received formal notice from Nasdaq stating that Ernexa has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2) for continued listing.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERNA:
- Ernexa Therapeutics expands Scientific Advisory Board
- Ernexa secures $6M in second closing under securities purchase agreement
- Eterna Therapeutics Implements 1-for-15 Reverse Stock Split
- Eterna Therapeutics trading halted, news pending
- Ernexa Therapeutics files to sell 57.05M shares of common stock for holders